Skip to main content
Terug
Watch Compare

Acumen Pharmaceuticals, Inc.

Datakwaliteit: 83%
ABOS
NASDAQ Manufacturing Chemicals
€ 2,47
▼ € 0,04 (-1,59%)
Marktkapitalisatie: 182,34 M
Prijs
€ 2,53
Marktkapitalisatie
182,34 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Debt/Equity of 0,33 — conservative balance sheet
Negative free cash flow of -115,54 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-115,42%
Onder sectorgemiddelde (-54,44%)
ROIC-71,28%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
0,33
Boven sectorgemiddelde (0,30)
Current Ratio6,02
Interest Coverage-29,32

Waardering

PE (TTM|NTM)
-1,50 | -1,77
Onder sectorgemiddelde (-1,49)
P/B Ratio1,96
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1385 peers)
Metriek Aandeel Sector Mediaan
P/E -1,5 -1,5
P/B 2,0 1,6
ROE % -115,4 -54,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,9
D/E 0,3 0,3

Koersdoel Analisten

5 analisten
Buy
Huidig
€ 2,47
+199.6%
Koersdoel
€ 7,40
€ 4,00
€ 8,00
€ 10,00
Vooruitzicht
Forward K/W -1,77
Forward WPA -€ 1,39
Omzet Sch. 0,0

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 1,39
-€ 1,39 – -€ 1,39
 0,0 1
FY2026 -€ 1,88
-€ 1,88 – -€ 1,88
 0,0 1

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,56 -€ 0,41 +26,3%
Q32025 -€ 0,68 -€ 0,44 +35,2%
Q22025 -€ 0,52 -€ 0,68 -31,1%
Q12025 -€ 0,55 -€ 0,48 +12,1%

ETFs Holding This Stock

BRUSX BRUSX
0,17% weight
BRSIX BRSIX
0,11% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -121,34 M
ROE -115,42% ROA -77,25%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -115,54 M
ROIC -71,28% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,33 Current Ratio 6,02
Interest Coverage -29,32 Asset Turnover N/A
Working Capital 110,20 M Tangible Book Value 93,17 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,50 Forward P/E -1,77
P/B Ratio 1,96 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -63,37%
Market Cap 182,34 M Enterprise Value 166,16 M
Per Share
EPS (Diluted TTM) -2,00 Revenue / Share N/A
FCF / Share -1,60 OCF / Share -1,60
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 95,22%
SBC-Adj. FCF -125,31 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -121,34 M -102,33 M -52,37 M -42,86 M -100,61 M
EPS (Diluted) -2,00 -1,71 -1,08 -1,06 —
Gross Profit — — — — —
Operating Income -123,83 M -114,02 M -61,14 M -45,24 M -19,58 M
EBITDA — — — — —
R&D Expenses 104,89 M 93,80 M 42,32 M 32,36 M 12,31 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 4,22 M 4,07 M 581.000,0 — —
Income Tax 0,0 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 122,83 M 238,99 M 310,13 M 196,59 M 230,33 M
Total Liabilities 52,40 M 57,18 M 43,15 M 7,81 M 5,15 M
Shareholders' Equity 70,43 M 181,82 M 266,97 M 188,78 M 225,18 M
Total Debt 31,16 M 29,42 M 29,90 M — —
Cash & Equivalents 53,99 M 35,63 M 66,89 M — 122,16 M
Current Assets 122,25 M 178,31 M 246,62 M 180,33 M 198,66 M
Current Liabilities 30,01 M 27,61 M 12,97 M 7,81 M —